2023
Placebo’s role in the rapid antidepressant effect
Sanacora G, Colloca L. Placebo’s role in the rapid antidepressant effect. Nature Mental Health 2023, 1: 820-821. DOI: 10.1038/s44220-023-00141-w.Peer-Reviewed Original ResearchRandomized placebo-controlled studyPlacebo-controlled studyRapid antidepressant effectsRapid antidepressant responseRapid antidepressant actionsStudy arm assignmentAntidepressant actionAntidepressant effectsAntidepressant responseSurgical anesthesiaTreatment assignmentHigh ratePlaceboAnesthesiaKetamine
2019
Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
Sanacora G, Kitay B, Wilkinson S. Chapter 35 The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives. 2019, 401-413. DOI: 10.1016/b978-0-12-813333-0.00035-4.Peer-Reviewed Original ResearchAntidepressant actionRapid onsetRapid-onset antidepressant actionRapid acting antidepressantsMajor depressive episodeClear unmet needActing antidepressantsAntidepressant treatmentDepressive episodeKetamine effectsClinical trialsDepressive disorderPreclinical studiesUnmet needSuch treatmentTreatmentComplicating factors
2016
Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
Hermes G, Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies. 2016, 73-98. DOI: 10.1007/978-3-319-42925-0_6.Peer-Reviewed Original ResearchAntidepressant activityPreclinical studiesAntidepressant actionKetamine's mechanismPreclinical literatureRodent modelsRapid onsetBrain-derived neurotrophic factor (BDNF) expressionBehavioral effectsClassic antidepressant drugsRapid antidepressant activityNeurotrophic factor expressionChronic stressor exposureReceptor-targeted drugsNovel drug developmentAntidepressant propertiesKetamine effectsClinical trialsAntidepressant drugsSynaptic plasticityReceptor activationClinical settingFactor expressionStressor exposureDurable effects
2011
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive AgentsBlood PressureDepressive Disorder, MajorDissociative DisordersFemaleGamma-Aminobutyric AcidGlutamic AcidHeart RateHumansKetamineMagnetic Resonance SpectroscopyMaleMiddle AgedOccipital LobeProtonsPsychiatric Status Rating ScalesPsychometricsRetrospective StudiesSingle-Blind MethodStatistics as TopicTime FactorsYoung AdultConceptsMajor depressive disorderAntidepressant effectsAntidepressant actionNeurotransmitter contentNMDA receptor antagonist ketamineProton magnetic resonance spectroscopy methodConventional antidepressant treatmentKetamine's antidepressant actionSingle intravenous doseSingle-blind conditionsAntidepressant treatmentChronic treatmentKetamine infusionIntravenous dosePharmacodynamic basisDepressive disorderAcute actionsMRS scansOccipital cortexDepressive symptomsDepression scoresRating ScaleBaseline measuresInfusionKetamine
2008
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.Peer-Reviewed Original ResearchMeSH KeywordsAcetatesAnimalsAvoidance LearningBehavioral SymptomsDepressionDisease Models, AnimalFood PreferencesGene Expression RegulationGlial Fibrillary Acidic ProteinGlutamic AcidIsotopesMagnetic Resonance SpectroscopyMaleNeurogliaNeuroprotective AgentsPrefrontal CortexRadionuclide ImagingRatsRats, Sprague-DawleyRiluzoleRNA, MessengerStatistics, NonparametricStress, PsychologicalSucroseSweetening AgentsConceptsChronic unpredictable stressPrefrontal cortexGlial dysfunctionGlial functionBehavioral deficitsDrug riluzoleOpen-label clinical trialMRNA expressionAmino acid neurotransmissionAntidepressant drug developmentDepressive-like behaviorPathophysiology of depressionEffects of riluzoleGlial cell metabolismMajor depressive disorderRat prefrontal cortexGFAP mRNA expressionProtein mRNA expressionNeurotransmitter system abnormalitiesGlia pathologyGlial pathologyRiluzole treatmentAntidepressant actionChronic treatmentGlutamate release